Skip to content
EN

Back to the catalog

adaptivebiotech.com
rss2American English

Adaptive Biotech

adaptivebiotech.com · American English

Adaptive Biotechnologies is harnessing the immune system to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.

rss2 wordpress content atom dc sy

Open the feed

https://www.adaptivebiotech.com/feed/

Last post
Apr 10, 2026
Posts in 24 h · 7 days · 30 days
0 · 0 · 0
Our last check
Answering
Served from
United States
Site title
Powering the Age of Immune Medicine
Text score at discovery
6,206
Format
rss2
Features in the feed
content, atom, dc, sy
Community
wordpress

Posts

What our queue read from this feed. Open one to read it here, or go to the site that published it.

  1. Predicting T Cell Recognition: New Insights from Large-Scale Activation Data
    Apr 10, 2026 · original
    A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell activation data can improve prediction of T cell receptor recognition, a longstanding challenge in computational immunology with implications for cancer and autoimmune disease. Predicting how T-cell receptors (TCRs) recognize peptide–MHC (pMHC) antigens is one of the central challenges in immunology today. It is also one of the hardest to solve. T cell recognition arises from complex molecular interactions, and even recent advances in protein structure prediction have not fully resolved which receptor-antigen pairs will lead to T cell activation. That question has broad relevance across immune-mediated diseases. In cancer, it could help researchers better understand antigen-specific immune responses relevant to target discovery and therapeutic design, while in autoimmune disease it may offe
  2. Adaptive Earns Cornerstone Recognition for LGBTQ+ Workplace Inclusion in HRC’s 2025 Corporate Equality Index
    Jan 7, 2025 · original
    The Human Rights Campaign (HRC) Foundation’s 2025 Corporate Equality Index (CEI) is the national benchmark on corporate policies, practices and benefits impacting LGBTQ+ employees. Each year, the CEI is a primary driving force for LGBTQ+ workplace inclusion and provides a valuable and objective score in the adoption of critical measures of an employer’s commitment to workplace equality. Today, we are proud to share that Adaptive Biotechnologies has received a score of 80 out of 100 . Adaptive’s 2025 CEI score is an important recognition of our ongoing efforts to enhance workforce protections and inclusivity for our LGBTQ+ team members as well as their families, friends, and colleagues. Adaptive is proudly committed to continually enhancing our programs and our culture of inclusion! At Adaptive, we focus on the development and commercialization of clinical products that improve people’s l
  3. Jim’s Journey: The Power of Collaboration in Blood Cancer Care
    Oct 24, 2024 · original
    Facing cancer takes courage. It also requires collaboration: patients and their physicians working together to gain the information they need throughout the treatment journey. At Adaptive, we are proud to develop advanced testing methods that can provide these insights as patients and their care teams manage blood cancer care. In honor of the important relationships between patients and their providers, this Blood Cancer Awareness Month, we sat down with Jim B., who lives with diffuse large B-cell lymphoma (DLBCL), and his hematologist, Dr. Jie Wang from Duke Blood Cancer Center, to discuss how clonoSEQ® testing supported his care. Jim has always thrived on building connections with others. Married to his wife, Anne, for 47 years, Jim earned his degrees in cognitive psychology and information science before pursuing a successful career in user interface, software and network engineering
  4. Pride Month at Adaptive: Celebrating Progress and Community
    Jun 27, 2024 · original
    Pride Month is an opportunity to celebrate the history and progress made by the lesbian, gay, bisexual, transgender, queer (LGBTQ+) community, while also reflecting on the ongoing challenges faced today. As the lead of the Adaptive Pride employee resource group (ERG), we arranged exciting programming with onsite lunches, social events, and speaking engagements focused on how to support, serve, and increase Adapter awareness and understanding of the LGBTQ+ community. We kicked off the month in the sweetest way possible—with a rainbow cookie baking demonstration. As we whipped up these colorful treats, we were reminded how diversity enriches our lives and our workplace. Each ingredient, like each person, adds its own unique flavor to the mix, creating something truly wonderful when we come together. Later in the month, we hosted a Lunch & Learn in collaboration with the Rainbow Center , a
  5. Decoding Public T-cell Signatures of Disease with Tens of Thousands of T-cell Receptor Repertoires
    Jun 7, 2024 · original
    In the ever-evolving field of immunology, the study of T-cell responses to various exposures is pivotal for unraveling the complexities of immune health and advancing new therapies that use these natural defenses. T cells, through their unique receptors, record the history of an individual’s immune challenges, such as infections, vaccinations or various chronic conditions, referred to as T-cell signatures. Collectively, these signatures are comprised of both T-cell responses that are individualistic as well as those that are public across populations with overlapping exposures and shared Human Leukocyte Antigens (HLAs). Understanding these signatures is crucial as they offer a window into the body’s adaptive immune responses, revealing how T cells differentiate and mobilize in the face of diverse threats. This knowledge is instrumental in developing targeted therapies and vaccines. By ma
  6. When the Doctor Becomes the Caregiver
    Mar 7, 2024 · original
    In honor of Multiple Myeloma Awareness Month, we sat down with Dr. Hamza Hashmi, a hematologist-oncologist from Memorial Sloan Kettering Cancer Center, to understand how his family’s personal experience with cancer has influenced his approach to treating and caring for patients living with myeloma and other plasma cell disorders . As an oncology specialist, Dr. Hashmi is accustomed to his friends and family turning to him for guidance or additional context when a loved one is diagnosed with cancer, as they seek ways to cope with the situation. His siblings are also physicians, and they often rely on one another for consults across their respective specialties. So, when he received a message from his brother with images of a patient’s labs in May 2023, he proceeded to provide his expertise as usual. “I went through the case and immediately recognized the unmistakable signs of advanced-sta
  7. Clinically Actionable Insights: A Q&A with Dr. Luciano Costa on the Final Analysis of MASTER
    Dec 1, 2023 · original
    In 2021, Susan Bobulsky sat down with Dr. Luciano Costa to learn about the initial results from the phase 2 MRD response-Adapted Sequential ThERapy (MASTER) trial. The trial evaluated daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) as induction therapy in patients with newly diagnosed multiple myeloma (MM), followed by autologous stem cell transplant (ASCT) and up to 8 cycles of Dara-KRd consolidation. Measurable residual disease (MRD) status measured by clonoSEQ® was used to modulate treatment duration and cessation. The findings represented a huge step forward for understanding how we should be personalizing treatment decisions based on MRD-negative status. Specifically, it examined the cessation of therapy in newly diagnosed multiple myeloma patients who showed deep MRD-negative responses to treatment. Data from the final analysis
  8. Immune Medicine in Action: How Adaptive Immunosequencing Helped Validate a Personalized Vaccine Trial in PDAC
    Aug 4, 2023 · original
    Over the past decade, the rapid advancement of immunotherapies has been revolutionary in several cancers. However, pancreatic ductal adenocarcinoma, or PDAC, has been described as a “cold tumor” where immunosuppression results in low T-cell infiltration and poor treatment responses to immunotherapy. PDAC is an aggressive form of cancer with an average 5-year survival rate of less than 10% and a nearly 90% rate of recurrence. In a 2017 publication 1 , Dr. Vinod Balachandran, surgical oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), worked with Adaptive to leverage our T-cell receptor beta (TCRB) sequencing assay on research that found long-term survivors of PDAC could mount spontaneous T-cell responses against tumor-specific neoantigens not shared among patients. From there, he hypothesized that personalized mRNA vaccines could provide clinical benefit. Results from Balachand
  9. Hope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care
    Mar 22, 2023 · original
    Every March, people and organizations celebrate Multiple Myeloma Awareness Month – using their voices to raise awareness about efforts to diagnose, treat, and support patients with multiple myeloma as well as inspire others on their blood cancer journeys. Earlier this month, Adapters had the privilege of hearing from Tiffany Williams, a 55-year-old multiple myeloma patient. Tiffany is a retired pediatric nurse practitioner turned patient advocate. More than that – she’s a mother, wife, sister, daughter and a fiercely supportive friend. Nearly 10 years ago, Tiffany began experiencing back pain. The previous year she had been treated by a neurologist for a herniated disc, so she booked another visit. This time, things quickly turned serious when an MRI revealed lesions on her spine that had metastasized. Given her medical background, she knew the prognosis wasn’t good and started to give u
  10. Among Multiple Myeloma Patients Receiving MRD Testing, Majority Report Meaningful Benefits
    Feb 22, 2023 · original
    The uncertainty associated with a multiple myeloma diagnosis can often be deeply frightening. Many patients and their loved ones find themselves overwhelmed searching for information about prognosis and treatment. Others may feel anxious not knowing whether their treatment is working, or, if in remission, whether the cancer may come back. This is why minimal residual disease (MRD) testing is so important. MRD testing can help to provide an accurate, ongoing picture of disease and risk status, offering a sense of control and comfort during a time when life may feel less manageable. Adaptive recently supported a survey of multiple myeloma patients conducted by HealthTree Foundation (formerly Myeloma Crowd), to assess and learn from real-world patients about their current awareness, use, and perceptions of MRD testing. With this knowledge, Adaptive and HealthTree can ensure patients and cli

Discovered by the rss-feed-index crawler, which checks each feed at most once a month.

Same record as JSON: https://api.agentalog.com/api/feeds/fd_adaptivebiotech_com_78fbb6ba3dd47aaa. More from this site: adaptivebiotech.com in the Feeds tab.